Clincosm LogoSign in Get a demo

multiple myeloma in relapse

Showing 1 - 25 of 62
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Multiple Myeloma in Relapse Trial in Shenzhen (BCMA/GPRC5D double CAR-T)

Recruiting
  • Multiple Myeloma in Relapse
  • BCMA/GPRC5D double CAR-T
  • Shenzhen, Guangdong, China
    Shenzhen Qianhai Shekou Free Trade Zone Hospital
Sep 28, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Jun 8, 2023

Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

Not yet recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Belantamab mafodotin, Venetoclax
  • (no location specified)
May 10, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T Cells Injection
  • (no location specified)
Feb 18, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (BCMA CAR-NK, Cyclophosphamide, Fludarabine

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • BCMA CAR-NK
  • +2 more
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T cells infusion
  • Kunming, Yunnan, China
  • +1 more
Feb 21, 2023

Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

Recruiting
  • Multiple Myeloma in Relapse
  • Aurora, Colorado
    University of Colorado Hospital
Jan 31, 2023

Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

Not yet recruiting
  • Multiple Myeloma, Refractory
  • Multiple Myeloma in Relapse
  • Autologous CAR-T cell therapy expressing the BAFF-ligand.
  • Cleveland, Ohio
    University Hospitals Seidman Cancer Center
Jan 11, 2023

Health Technology Intervention on Patient Activation in Multiple

Not yet recruiting
  • Multiple Myeloma in Relapse
  • +3 more
    • (no location specified)
    Jan 9, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

    Active, not recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • Poitiers, France
      CHU Poitiers
    Jan 9, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory Trial (Pomalidomide 4 mg every day in cycle 1,

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • +2 more
    • Pomalidomide 4 mg every day in cycle 1
    • +4 more
    • (no location specified)
    Nov 16, 2022

    Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in China, Taiwan (TJ202 and Dexamethasone)

    Active, not recruiting
    • Multiple Myeloma in Relapse
    • Refractory Multiple Myeloma
    • TJ202 and Dexamethasone
    • Beijing, Beijing, China
    • +17 more
    Oct 17, 2022

    Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in China, Taiwan (TJ202, Lenalidomide and Dexamethasone,

    Active, not recruiting
    • Multiple Myeloma in Relapse
    • Refractory Multiple Myeloma
    • TJ202, Lenalidomide and Dexamethasone
    • Lenalidomide and Dexamethasone
    • Beijing, Beijing, China
    • +40 more
    Oct 17, 2022

    Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • +8 more
    • Belantamab Mafodotin-Blmf
    • +3 more
    • (no location specified)
    Oct 13, 2022

    Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II Trial in London (Rivaroxaban, ASA)

    Recruiting
    • Multiple Myeloma in Relapse
    • +5 more
    • London, Ontario, Canada
      London Health Sciences Centre
    Oct 3, 2022

    Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Aug 8, 2022

    Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission Trial in United States (FOR46)

    Completed
    • Multiple Myeloma
    • +2 more
    • San Francisco, California
    • +6 more
    Jul 25, 2022

    Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone Trial in Worldwide (HPN217)

    Recruiting
    • Multiple Myeloma in Relapse
    • +3 more
    • Gilbert, Arizona
    • +17 more
    Jul 21, 2022

    Defining Clinical Potential of Mass Response asBiomarker for

    Recruiting
    • Stage III Breast Cancer
    • +5 more
      • Columbus, Georgia
        Columbus Regional Research Institute, John B. Amos Cancer Center
      Jul 13, 2022

      Mass Accumulation Rate asPredictive Biomarker in Multiple

      Recruiting
      • Multiple Myeloma in Relapse
        • Duarte, California
        • +5 more
        Jul 13, 2022

        Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Israel (ixazomib-pomalidomide-dexamethasone)

        Recruiting
        • Multiple Myeloma in Relapse
        • Refractory Multiple Myeloma
        • Afula, Israel
        • +7 more
        Jul 10, 2022

        Multiple Myeloma in Relapse Trial in Paris (Daratumumab/Lenalidomide/Dexamethasone for 24 months,

        Recruiting
        • Multiple Myeloma in Relapse
        • Daratumumab/Lenalidomide/Dexamethasone for 24 months
        • Daratumumab/Lenalidomide/Dexamethasone until progression
        • Paris, France
          Saint Antoine Hospital - Hematology Department
        Jun 10, 2022

        Kyprolis® in Combination With Revlimid® and Dexamethasone or

        Recruiting
        • Multiple Myeloma in Relapse
        • Frankfurt, Germany
          Centrum für Hämatologie und Onkologie Bethanien
        Jun 2, 2022

        Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

        Recruiting
        • Multiple Myeloma in Relapse
        • Multiple Myeloma, Refractory
        • APRIL CAR-T cells
        • Hangzhou, Zhejiang, China
          The First Affiliated Hospital，College of Medicine, Zhejiang Univ
        May 3, 2022